AMPA receptor subunit and splice variant expression in the DLPFC of schizophrenic subjects and rhesus monkeys chronically administered antipsychotic drugs

Schizophrenia Research

Volumn 90, Issue 1-3, 2007, Pages 28-40

  O'Connor, J A ^a,b   Muly, E C ^a,c   Arnold, S E ^d   Hemby, S E ^b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

^c EMORY UNIVERSITY   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

AMPA; Antipsychotic; Dorsolateral prefrontal cortex; Flip flop splice variants; Rhesus monkey; Schizophrenia

Indexed keywords

AMPA RECEPTOR; AMPA RECEPTOR 1; AMPA RECEPTOR 3; CHLORPROMAZINE; CLOZAPINE; GLUTAMIC ACID; HALOPERIDOL; MESSENGER RNA; NEUROLEPTIC AGENT; RISPERIDONE; THIORIDAZINE; TIOTIXENE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BRAIN TISSUE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; FEMALE; HUMAN; HUMAN TISSUE; MALE; NEUROTRANSMISSION; NUCLEOTIDE SEQUENCE; PATHOPHYSIOLOGY; POLYMERASE CHAIN REACTION; PREFRONTAL CORTEX; PRIMATE; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ASSAY; RHESUS MONKEY; SCHIZOPHRENIA; UNITED STATES;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ANTIPSYCHOTIC AGENTS; CLOZAPINE; FEMALE; GENE EXPRESSION; HALOPERIDOL; HUMANS; MACACA MULATTA; MALE; MIDDLE AGED; PREFRONTAL CORTEX; PROTEIN ISOFORMS; RECEPTORS, AMPA; RNA, MESSENGER; SCHIZOPHRENIA; SYNAPTIC TRANSMISSION;

EID: 33846644390     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2006.10.004     Document Type: Article

References (88)

1. Anand A., Charney D.S., Oren D.A., Berman R.M., Hu X.S., Cappiello A., and Krystal J.H. Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-d-aspartate receptor antagonists. Arch. Gen. Psychiatry 57 3 (2000) 270-276
2. Arnold S.E., Gur R.E., Shapiro R.M., Fisher K.R., Moberg P.J., Gibney M.R., Gur R.C., Blackwell P., and Trojanowski J.Q. Prospective clinicopathologic studies of schizophrenia: accrual and assessment of patients. Am. J. Psychiatry 152 5 (1995) 731-737
3. Bonnet G., Tyagi S., Libchaber A., and Kramer F.R. Thermodynamic basis of the enhanced specificity of structured DNA probes. Proc. Natl. Acad. Sci. U. S. A. 96 11 (1999) 6171-6176
4. Brene S., Messer C., and Nestler E.J. Expression of messenger RNAs encoding ionotropic glutamate receptors in rat brain: regulation by haloperidol. Neuroscience 84 3 (1998) 813-823
5. Bun H., Disdier B., Aubert C., and Catalin J. Interspecies variability and drug interactions of clozapine metabolism by microsomes. Fundam. Clin. Pharmacol. 13 5 (1999) 577-581
6. Bunney W.E., and Bunney B.G. Evidence for a compromised dorsolateral prefrontal cortical parallel circuit in schizophrenia. Brain Res. Brain Res. Rev. 31 2-3 (2000) 138-146
7. Bustin S.A. Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays. J. Mol. Endocrinol. 25 2 (2000) 169-193
8. Bustin S.A., and Nolan T. Pitfalls of quantitative real-time reverse-transcription polymerase chain reaction. J. Biomol. Tech. 15 3 (2004) 155-166
9. Carroll R.C., Beattie E.C., von Zastrow M., and Malenka R.C. Role of AMPA receptor endocytosis in synaptic plasticity. Nat. Rev., Neurosci. 2 5 (2001) 315-324
10. 1 receptor stimulation. J. Neurosci. 24 6 (2004) 1446-1450
11. 1 receptor stimulation. Science 287 5460 (2000) 2020-2022
12. 1-like dopamine receptors in the primate brain: a PET study. Psychopharmacology (Berl) 185 1 (2006) 29-35
13. Coyle J.T., Tsai G., and Goff D.C. Ionotropic glutamate receptors as therapeutic targets in schizophrenia. Curr. Drug Target CNS Neurol. Disord. 1 2 (2002) 183-189
14. Dingledine R., Borges K., Bowie D., and Traynelis S.F. The glutamate receptor ion channels. Pharmacol. Rev. 51 1 (1999) 7-61
15. Domino E.F., Chodoff P., and Corssen G. Pharmacologic effects of Ci-581, a new dissociative anesthetic, in man. Clin. Pharmacol. Ther. 6 (1965) 279-291
16. Dorph-Petersen K.A., Pierri J.N., Perel J.M., Sun Z., Sampson A.R., and Lewis D.A. The influence of chronic exposure to antipsychotic medications on brain size before and after tissue fixation: a comparison of haloperidol and olanzapine in macaque monkeys. Neuropsychopharmacology 30 9 (2005) 1649-1661
17. Dracheva S., Marras S.A., Elhakem S.L., Kramer F.R., Davis K.L., and Haroutunian V. N-Methyl-d-aspartic acid receptor expression in the dorsolateral prefrontal cortex of elderly patients with schizophrenia. Am. J. Psychiatry 158 9 (2001) 1400-1410
18. Dracheva S., McGurk S.R., and Haroutunian V. mRNA expression of AMPA receptors and AMPA receptor binding proteins in the cerebral cortex of elderly schizophrenics. J. Neurosci. Res. 79 6 (2005) 868-878
19. DSM-IV. Diagnostic and Statistical Manual of Mental Disorders (1994), American Psychiatric Association, Washington, DC
20. Eastwood S.L., Porter R.H., and Harrison P.J. The effect of chronic haloperidol treatment on glutamate receptor subunit (GluR1, GluR2, KA1, KA2, NR1) mRNAs and glutamate binding protein mRNA in rat forebrain. Neurosci. Lett. 212 3 (1996) 163-166
21. Eastwood S.L., Burnet P.W., and Harrison P.J. GluR2 glutamate receptor subunit flip and flop isoforms are decreased in the hippocampal formation in schizophrenia: a reverse transcriptase-polymerase chain reaction (RT-PCR) study. Brain Res. Mol. Brain Res. 44 1 (1997) 92-98
22. Fitzgerald L.W., Deutch A.Y., Gasic G., Heinemann S.F., and Nestler E.J. Regulation of cortical and subcortical glutamate receptor subunit expression by antipsychotic drugs. J. Neurosci. 15 3 Pt 2 (1995) 2453-2461
23. Francois C., Yelnik J., Tande D., Agid Y., and Hirsch E.C. Dopaminergic cell group A8 in the monkey: anatomical organization and projections to the striatum. J. Comp. Neurol. 414 3 (1999) 334-347
24. Goff D.C., and Coyle J.T. The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am. J. Psychiatry 158 9 (2001) 1367-1377
25. Haber S.N., and Gdowski M.J. The basal ganglia. In: Paxinos G., and Mai J.K. (Eds). The Human Nervous System (2004), Elsevier, San Diego 676-738
26. Hayashi Y., Shi S.H., Esteban J.A., Piccini A., Poncer J.C., and Malinow R. Driving AMPA receptors into synapses by LTP and CaMKII: requirement for GluR1 and PDZ domain interaction. Science 287 5461 (2000) 2262-2267
27. Healy D.J., and Meador-Woodruff J.H. Clozapine and haloperidol differentially affect AMPA and kainate receptor subunit mRNA levels in rat cortex and striatum. Brain Res. Mol. Brain Res. 47 1-2 (1997) 331-338
28. Healy D.J., Haroutunian V., Powchik P., Davidson M., Davis K.L., Watson S.J., and Meador-Woodruff J.H. AMPA receptor binding and subunit mRNA expression in prefrontal cortex and striatum of elderly schizophrenics. Neuropsychopharmacology 19 4 (1998) 278-286
29. Hemby S.E., Ginsberg S.D., Brunk B., Arnold S.E., Trojanowski J.Q., and Eberwine J.H. Gene expression profile for schizophrenia: discrete neuron transcription patterns in the entorhinal cortex. Arch. Gen. Psychiatry 59 7 (2002) 631-640
30. 1 dopamine receptor: a putative neurochemical and behavioral link to cocaine action. J. Cell. Physiol. 191 1 (2002) 17-27
31. Hyman S.E., and Nestler E.J. Initiation and adaptation: a paradigm for understanding psychotropic drug action. Am. J. Psychiatry 153 2 (1996) 151-162
32. Javitt D.C., and Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatry 148 10 (1991) 1301-1308
33. Jayakar S.S., and Dikshit M. AMPA receptor regulation mechanisms: future target for safer neuroprotective drugs. Int. J. Neurosci. 114 6 (2004) 695-734
34. Kalivas P.W., and Stewart J. Dopamine transmission in the initiation and expression of drug- and stress-induced sensitization of motor activity. Brain Res. Brain Res. Rev. 16 3 (1991) 223-244
35. 2 receptors. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 27 7 (2003) 1081-1090
36. Koike M., Tsukada S., Tsuzuki K., Kijima H., and Ozawa S. Regulation of kinetic properties of GluR2 AMPA receptor channels by alternative splicing. J. Neurosci. 20 6 (2000) 2166-2174
37. Krystal J.H., Karper L.P., Seibyl J.P., Freeman G.K., Delaney R., Bremner J.D., Heninger G.R., Bowers Jr. M.B., and Charney D.S. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch. Gen. Psychiatry 51 3 (1994) 199-214
38. Krystal J.H., D'Souza D.C., Karper L.P., Bennett A., Abi-Dargham A., Abi-Saab D., Cassello K., Bowers Jr. M.B., Vegso S., Heninger G.R., and Charney D.S. Interactive effects of subanesthetic ketamine and haloperidol in healthy humans. Psychopharmacology (Berl) 145 2 (1999) 193-204
39. Lahti A.C., Koffel B., LaPorte D., and Tamminga C.A. Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology 13 1 (1995) 9-19
40. Lahti A.C., Weiler M.A., Tamara Michaelidis B.A., Parwani A., and Tamminga C.A. Effects of ketamine in normal and schizophrenic volunteers. Neuropsychopharmacology 25 4 (2001) 455-467
41. Lewis D.A. The human brain revisited: opportunities and challenges in postmortem studies of psychiatric disorders. Neuropsychopharmacology 26 2 (2002) 143-154
42. Lewis D.A., and Akil M. Cortical dopamine in schizophrenia: strategies for postmortem studies. J. Psychiatr. Res. 31 2 (1997) 175-195
43. Lidow M.S. Calcium signaling dysfunction in schizophrenia: a unifying approach. Brain Res. Brain Res. Rev. 43 1 (2003) 70-84
44. 2-dopaminergic receptors in the primate cerebral cortex. Proc. Natl. Acad. Sci. U. S. A. 91 10 (1994) 4353-4356
45. 4 dopamine receptor mRNAs in the primate cerebral cortex vs. neostriatum: effects of chronic treatment with typical and atypical antipsychotic drugs. J. Pharmacol. Exp. Ther. 283 2 (1997) 939-946
46. 4 dopamine receptor mRNAs in the primate cerebral cortex vs. neostriatum: effects of chronic treatment with typical and atypical antipsychotic drugs. J. Pharmacol. Exp. Ther. 283 2 (1997) 939-946
47. 5 dopamine receptors in the primate prefrontal cortex by chronic treatment with antipsychotic drugs. J. Pharmacol. Exp. Ther. 281 1 (1997) 597-603
48. Luby E.D., Cohen B.D., Rosenbaum G., Gottlieb J.S., and Kelley R. Study of a new schizophrenomimetic drug, sernyl. AMA Arch. Neurol. Psychiatry 81 3 (1959) 363-369
49. Lynd-Balta E., and Haber S.N. The organization of midbrain projections to the ventral striatum in the primate. Neuroscience 59 3 (1994) 609-623
50. MacDonald M.L., Eaton M.E., Dudman J.T., and Konradi C. Antipsychotic drugs elevate mRNA levels of presynaptic proteins in the frontal cortex of the rat. Biol. Psychiatry 57 9 (2005) 1041-1051
51. Malenka R.C. Synaptic plasticity and AMPA receptor trafficking. Ann. N. Y. Acad. Sci. 1003 (2003) 1-11
52. McCoy L., Cox C., and Richfield E.K. Antipsychotic drug regulation of AMPA receptor affinity states and GluR1, GluR2 splice variant expression. Synapse 28 3 (1998) 195-207
53. Meador-Woodruff J.H., and Healy D.J. Glutamate receptor expression in schizophrenic brain. Brain Res. Brain Res. Rev. 31 2-3 (2000) 288-294
54. Meador-Woodruff J.H., King R.E., Damask S.P., and Bovenkerk K.A. Differential regulation of hippocampal AMPA and kainate receptor subunit expression by haloperidol and clozapine. Mol. Psychiatry 1 1 (1996) 41-53
55. Meng Y., Zhang Y., and Jia Z. Synaptic transmission and plasticity in the absence of AMPA glutamate receptor GluR2 and GluR3. Neuron 39 1 (2003) 163-176
56. Mirnics K., Middleton F.A., Marquez A., Lewis D.A., and Levitt P. Molecular characterization of schizophrenia viewed by microarray analysis of gene expression in prefrontal cortex. Neuron 28 1 (2000) 53-67
57. Mirnics K., Middleton F.A., Stanwood G.D., Lewis D.A., and Levitt P. Disease-specific changes in regulator of G-protein signaling 4 (RGS4) expression in schizophrenia. Mol. Psychiatry 6 3 (2001) 293-301
58. Moghaddam B., Adams B., Verma A., and Daly D. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J. Neurosci. 17 8 (1997) 2921-2927
59. Mosbacher J., Schoepfer R., Monyer H., Burnashev N., Seeburg P.H., and Ruppersberg J.P. A molecular determinant for submillisecond desensitization in glutamate receptors. Science 266 5187 (1994) 1059-1062
60. Mueller H.T., and Meador-Woodruff J.H. NR3A NMDA receptor subunit mRNA expression in schizophrenia, depression and bipolar disorder. Schizophr. Res. 71 2-3 (2004) 361-370
61. O'Connor J.A., Hasenkamp W., Horman B.M., Muly E.C., and Hemby S.E. Region specific regulation of NR1 in rhesus monkeys following chronic antipsychotic drug administration. Biol. Psychiatry 60 6 (2006) 659-662
62. Ohl F., Jung M., Xu C., Stephan C., Rabien A., Burkhardt M., Nitsche A., Kristiansen G., Loening S.A., Radonic A., and Jung K. Gene expression studies in prostate cancer tissue: which reference gene should be selected for normalization?. J. Mol. Med. 83 12 (2005) 1014-1024
63. Olney J.W., and Farber N.B. Glutamate receptor dysfunction and schizophrenia. Arch. Gen. Psychiatry 52 12 (1995) 998-1007
64. Palmer C.L., Cotton L., and Henley J.M. The molecular pharmacology and cell biology of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors. Pharmacol. Rev. 57 2 (2005) 253-277
65. Passafaro M., Piech V., and Sheng M. Subunit-specific temporal and spatial patterns of AMPA receptor exocytosis in hippocampal neurons. Nat. Neurosci. 4 9 (2001) 917-926
66. PDR. Physician's Desk Reference (1996), Medical Economics, Oradell, NJ
67. PDR. Physicians' Desk Reference (2006), Thomson PDR, Montvale, NJ
68. Preuss T.M. Do rats have prefrontal cortex? The Rose-Woolsey-Akert Program reconsidered. J. Cogn. Neurosci. 7 1 (1995) 1-24
69. Preuss T.M. The discovery of cerebral diversity: an unwelcome scientific revolution. In: Falk D., and Gibson K. (Eds). Evolutionary Anatomy of the Primate Cerebral Cortex (2001), Cambridge University Press, Cambridge 138-164
70. Robinson T.E., and Berridge K.C. The psychology and neurobiology of addiction: an incentive-sensitization view. Addiction 95 Suppl 2 (2000) S91-S117
71. Shi S.H., Hayashi Y., Petralia R.S., Zaman S.H., Wenthold R.J., Svoboda K., and Malinow R. Rapid spine delivery and redistribution of AMPA receptors after synaptic NMDA receptor activation. Science 284 5421 (1999) 1811-1816
72. Shi S., Hayashi Y., Esteban J.A., and Malinow R. Subunit-specific rules governing AMPA receptor trafficking to synapses in hippocampal pyramidal neurons. Cell 105 3 (2001) 331-343
73. Smith W.B., Starck S.R., Roberts R.W., and Schuman E.M. Dopaminergic stimulation of local protein synthesis enhances surface expression of GluR1 and synaptic transmission in hippocampal neurons. Neuron 45 5 (2005) 765-779
74. Snyder S.H. Phencyclidine. Nature 285 5764 (1980) 355-356
75. Sommer B., Keinanen K., Verdoorn T.A., Wisden W., Burnashev N., Herb A., Kohler M., Takagi T., Sakmann B., and Seeburg P.H. Flip and flop: a cell-specific functional switch in glutamate-operated channels of the CNS. Science 249 4976 (1990) 1580-1585
76. Spurney C.F., Baca S.M., Murray A.M., Jaskiw G.E., Kleinman J.E., and Hyde T.M. Differential effects of haloperidol and clozapine on ionotropic glutamate receptors in rats. Synapse 34 4 (1999) 266-276
77. Stafford J.E., Jackson L.S., Forrest T.J., Barrow A., and Palmer R.F. Haloperidol pharmacokinetics: a preliminary study in rhesus monkeys using a new radioimmunoassay procedure. J. Pharmacol. Methods 6 4 (1981) 261-279
78. Stine C.D., Lu W., and Wolf M.E. Expression of AMPA receptor flip and flop mRNAs in the nucleus accumbens and prefrontal cortex after neonatal ventral hippocampal lesions. Neuropsychopharmacology 24 3 (2001) 253-266
79. Torrey E.F., Webster M., Knable M., Johnston N., and Yolken R.H. The Stanley Foundation Brain Collection and Neuropathology Consortium. Schizophr. Res. 44 2 (2000) 151-155
80. Tsai G., and Coyle J.T. Glutamatergic mechanisms in schizophrenia. Annu. Rev. Pharmacol. Toxicol. 42 (2002) 165-179
81. Tyagi S., and Kramer F.R. Molecular beacons: probes that fluoresce upon hybridization. Nat. Biotechnol. 14 3 (1996) 303-308
82. Vanderschuren L.J., and Kalivas P.W. Alterations in dopaminergic and glutamatergic transmission in the induction and expression of behavioral sensitization: a critical review of preclinical studies. Psychopharmacology (Berl) 151 2-3 (2000) 99-120
83. Vandesompele J., De Preter K., Pattyn F., Poppe B., Van Roy N., De Paepe A., and Speleman F. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 3 7 (2002) (RESEARCH0034)
84. Vawter M.P., Crook J.M., Hyde T.M., Kleinman J.E., Weinberger D.R., Becker K.G., and Freed W.J. Microarray analysis of gene expression in the prefrontal cortex in schizophrenia: a preliminary study. Schizophr. Res. 58 1 (2002) 11-20
85. Wang Y., TesFaye E., Yasuda R.P., Mash D.C., Armstrong D.M., and Wolfe B.B. Effects of post-mortem delay on subunits of ionotropic glutamate receptors in human brain. Brain Res. Mol. Brain Res. 80 2 (2000) 123-131
86. Weinberger D.R., Berman K.F., and Zec R.F. Physiologic dysfunction of dorsolateral prefrontal cortex in schizophrenia: I. Regional cerebral blood flow evidence. Arch. Gen. Psychiatry 43 2 (1986) 114-124
87. Williams S.M., and Goldman-Rakic P.S. Widespread origin of the primate mesofrontal dopamine system. Cereb. Cortex 8 4 (1998) 321-345
88. 2 receptor regulation of AMPA receptor-mediated excitotoxicity. J. Neurosci. 25 17 (2005) 4385-4395